Patent EA-001929-B1 (EA)
Title: Method of treating a disease in a mammal and zwitterionic composition
Inventor: THEODORE T RONALD
IPC: A61P3/08
Filed: 1997-02-13
Abstract: 1. Use a zwitterionic compound comprising essentially an amphoteric zwitterionic compound or a pharmaceutically acceptable salt thereof, the zwitterionic compound is an aliphatic or heterocyclic compound having at least one bond carbon-nitrogen, and the acid group is selected from SO3, and COO, and the alkaline group is selected from OH, N<+>, N<+>H and NH2 for preparing a medicament adapted for use as a biologic response modifier in treating cancer, reducing cancer pains, an autoimmune disease, an infection disease or relieving an inflammatory processes in a mammal. 2. Use of claim 1, wherein the zwitterion compound comprises a six member heterocyclic ring with a nitrogen atom as a part of the ring. 3. Use of claim 1, wherein heterocycle comprises two nitrogen atoms and acid and alkaline groups connected by at least one -CH2- group to the acid group and alkaline group. 4. Use of claim 1, wherein the zwitterion compound comprises the structural formula:  (H) ( alkaline group- (CH2)n-1-3-N-(CH2)n-1-3 in which n changes from 1 to 3 and in which the alkaline group is selected from OH, N<+>, N<+>H and NH2 and the acid group is selected from SO3, and COO. 5. Use of claim 1, wherein the zwitterion compound is selected from the following compounds and combinations thereof     6. Use of any of the preceding claim, wherein comprises administering the zwitterion from about 0.1mg/kg to about 5000mg/kg to the body weight of the mammal to be treated. 7. Use of claim 1, wherein the zwitterion composition comprises an amino acid and human serum. 8. Use of any of the preceding claim, wherein includes the treatment of a cancer tumor-containing disease by macrophage infiltration and shrinkage of the tumor. 9. Use of any of claims 1 to 7, wherein includes the treatment of diseases to produce giant platelets and histocytes. 10. Use of any of claims 1 to 7, wherein includes the treatment of the disease of hepatitis. 11. Use of any of claims 1 to 7, wherein includes the treatment of autoimmune diseases. 12. Use of any of claims 1 to 7, wherein includes the treatment of reducing pain. 13. of any of claims 1 to 7, wherein includes the treatment of reducing viral activity. 14. Use of any of claims 1 to 7, wherein includes the treatment of tumorous cancer. 15. Use of any of claims 1 to 7, wherein treatment includes reducing the level of alkaline phosphatase in a mammal. 16. A zwitterion composition adapted for use in the treatment of cancer, autoimmune disease, infection disease, reducing an inflammatory process in a mammal, which composition comprises: a) a therapeutic effective amount of a zwitterion compound as an active ingredient of one of claims 1 or 5or the pharmaceutically acceptable salt thereof; b) a pharmaceutically acceptable carrier for the zwitterion compound; and c) a compound selected from the group consisting of: amino acid, human serum, antibiotics and vitamins, and combinations thereof. 17. A compoition of claim 16, wherein comprises the zwitterion compound from about 0.1mg/kg to about 5000mg/kg to the body weight of the mammal to be treated.